Effective Management of Diabetes in Arab Region: Insights and Strategies
By Melike Belenli Gümüş
November 14, 2024
Introduction
Diabetes prevalence in the Arab region has surged, placing a heavy economic strain on healthcare systems. This increase is largely due to factors such as obesity, rapid urbanisation, and sedentary lifestyles. Effective diabetes management is crucial for maintaining optimal health and preventing complications. An expert consensus statement from Arab Diabetes Forum (ADF) has established key strategies, including preoperative risk assessment, obesity management, and fasting guidelines during Ramadan. By understanding these approaches, individuals can better manage their condition and improve their quality of life.
Integration of Global Standards and Regional Data
The ADF, comprising endocrinologists from various Arab countries, has developed tailored recommendations to improve diabetes management and treatment quality across the region. Their guideline integrates global standards from organisations like the American Diabetes Association (ADA), International Society for Pediatric and Adolescent Diabetes (ISPAD), American Association of Clinical Endocrinology (AACE), National Institute for Health and Care Excellence (NICE), and International Diabetes Federation (IDF), along with regional data. It emphasises evidence-based recommendations and was formulated through collaborative discussions with specialists, including pharmacists and dietitians.
Preoperative Risk Assessment
Before elective surgeries, a thorough preoperative risk assessment is essential for individuals with diabetes. This is particularly important for those at high risk of ischemic heart disease, autonomous neuropathy, or renal failure. The target HbA1c level should be below 8%, and blood glucose should range between 100–180 mg/dL within four hours of surgery. These measures help minimise surgical complications and promote faster recovery.
Obesity and Diabetes
Obesity significantly increases the risk of developing type 2 diabetes. In the Eastern Mediterranean Region, obesity prevalence is high, largely due to unhealthy diets. Managing obesity can delay the progression to type 2 diabetes and may even induce remission. A holistic approach, including physical activity, diet, behavioural therapy, and metabolic surgery, is recommended. This comprehensive strategy addresses the root causes of obesity and supports long-term health improvements.
Figure 1. Medication that should be avoided in diabetic patients.
Fasting During Ramadan
Many Muslims with diabetes choose to fast during Ramadan, despite religious permissions to abstain. Over the past 20 years, recommendations for fasting have evolved from expert opinions to evidence-based guidelines. It is crucial for individuals with diabetes to consult healthcare professionals before fasting. This ensures that their health is not compromised and that they can safely observe the fast.
Insulin Therapy for Children and Adolescents
Insulin therapy is vital for managing type 1 diabetes in children and adolescents. Rapid-acting insulins, such as Lispro, Aspart, and Glulisine, improve postprandial glucose control. These should be administered 10–15 minutes before meals to match food consumption and reduce hypoglycaemia risk. Basal insulin analogues provide consistent insulin release, preventing ketogenesis and hepatic glucose output. This tailored approach ensures effective diabetes management in young patients.
Conclusion
Effective diabetes management requires a multifaceted approach, including preoperative risk assessment, obesity management, and tailored insulin therapy. By following these strategies, individuals can better manage their condition and improve their overall health. For those observing Ramadan, consulting healthcare professionals is essential to ensure safe fasting practices. Therefore, the recommendations provided by the Arab Diabetes Forum are crucial for enhancing diabetes management in the region, as they integrate global best practices with local insights to improve treatment quality and patient outcomes.
🌍 *Could a twice-yearly shot revolutionize HIV prevention?*
Gilead Sciences has submitted key applications to the EMA for lenacapavir, a groundbreaking HIV-1 capsid inhibitor designed for use as pre-exposure prophylaxis (PrEP). With promising trial results indicating a significant reduction in HIV infections, this innovation could enhance adherence to prevention strategies globally. Discover more about this game-changing development!
🌍 Can collaboration redefine Africa’s health landscape?
A newly signed Memorandum of Understanding between Africa CDC and Global Health EDCTP3 promises to enhance health research, clinical trials, and pandemic preparedness on the continent. With a focus on training, local manufacturing, and equitable partnerships, this initiative aims to address pressing global health challenges while improving health outcomes across Africa.
Look into the details of this transformative partnership and its implications for the future of healthcare in the region!
🚨 Are we doing enough to tackle the imminent breast cancer crisis in Africa?
A recent WHO report reveals alarming trends, predicting that 135,000 women could succumb to breast cancer by 2040 unless urgent actions are taken. The report highlights critical gaps in healthcare infrastructure and capacity, emphasizing the need for investment in screening programs and professional training to improve outcomes across the continent.
Review the full article to explore the necessary steps towards reinforcing breast cancer control measures in Africa.
#SyenzaNews #globalhealth #oncology #HealthTech
When you partner with Syenza, it’s like a Nuclear Fusion.
Our expertise are combined with yours, and we contribute clinical expertise and advanced degrees in
health policy, health economics, systems analysis, public finance, business, and project management.
You’ll also feel our high-impact global and local perspectives with cultural intelligence.